Skip to main content
SpringerLink
Log in

Chancen optimieren, Risiken minimieren

Der Einsatz starker Opiode in der Hausarztpraxis

  • FORTBILDUNG_ÜBERSICHT
  • Published:
MMW - Fortschritte der Medizin Aims and scope

Zusammenfassung

Die Linderung von Schmerzen gehört zu den zentralen Aufgaben des Hausarztes. Starke Analgetika sind eine der hierfür zu Verfügung stehenden Optionen und erfreuen sich einer zunehmenden Beliebtheit. Was aber tun, wenn Opioide nicht den in sie gesetzten Erwartungen entsprechen oder ihre Nebenwirkung mitunter belastender werden als der Schmerz selbst? Hier bekommen Sie das Rüstzeug für diese Situationen.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. American Pain Society, American Academy of Pain Medicine. Use of chronic opioid therapy in chronic non-cancer pain.

  2. Arbeitsgemeinschaft wissenschaftlich medizinischer Fachgesellschaften. LONTS - Langzeitanwendung von Opioiden bei nicht tumorbedingten Schmerzen. Verfügbar online über:http://www.awmf.org/uploads/tx_szleitlinien/041-003l.pdf. Zuletzt aufgerufen am 16.09.2013

  3. Berland D, Rodgers P. Rational use of opioids for management of chronic nonterminal pain. Am Fam Physician 2012;86(3):252–258

    PubMed  Google Scholar 

  4. Prommer E, Ficek B. Management of pain in the elderly at the end of life. Drugs Aging 2012;29(4):285–305

    Article  PubMed  CAS  Google Scholar 

  5. Sarzi-Puttini P, Vellucci R, Zuccaro SM, Cherubino P, Labianca R, Fornasari D. The appropriate treatment of chronic pain. Clin Drug Investig 2012;32(Suppl 1):21–33

    CAS  Google Scholar 

  6. Reder RF. Opioid formulations:tailoring to the needs in chronic pain. Eur J Pain 2001;5(suppl A):109–111

    Article  PubMed  CAS  Google Scholar 

  7. Waldhoer M, Bartlett SE, Whistler JL. Opioid receptors. Annual Review of Biochemistry 2004;73:953–990

    Article  PubMed  CAS  Google Scholar 

  8. Ballantyne JC, Shin NS. Efficacy of opioids for chronic pain:a review of the evidence. Clin J Pain 2008;24(6):469–478

    Article  PubMed  Google Scholar 

  9. Ballantyne JC. Safe and effective when used as directed”:the case of chronic use of opioid analgesics. J Med Toxicol 2012;8(4):417–423

    Article  PubMed  CAS  Google Scholar 

  10. Camilleri M. Opioid-induced constipation: challenges and therapeutic opportunities. Am J Gastroenterol 2011;106(5):835–842

    Article  PubMed  CAS  Google Scholar 

  11. Manchikanti L, Vallejo R, Manchikanti KN, Benyamin RM, Datta S, Christo PJ. Effectiveness of long-term opioid therapy for chronic non-cancer pain. Pain Physician 2011;4(2):133–156

    Google Scholar 

  12. Martell BA, O’Connor PG, Kerns RD, Becker WC, Morales KH, Kosten TR, Fiellin DA. Systematic review:opioid treatment for chronic back pain:prevalence, efficacy, and association with addiction. Ann Intern Med 2007;146(2):116–127

    Article  PubMed  Google Scholar 

  13. National Opioid Use Guideline Group (NOUGG). Canadian guideline for safe and effective use of opioids for chronic non-cancer Pain 2010.

    Google Scholar 

  14. Nelsen D Jr. Opioids for the management of non-cancer pain. J Ark Med Soc 2013;109(12):252–253

    PubMed  Google Scholar 

  15. Leppert W. The role of opioid receptor antagonists in the treatment of opioid-induced constipation:a review. Adv Ther 2010;27(10):714–730

    Article  PubMed  CAS  Google Scholar 

  16. Davis MP. Twelve reasons for considering buprenorphine as a frontline analgesic in the management of pain. J Support Oncol 2012;10(6):209–219

    Article  PubMed  CAS  Google Scholar 

  17. Garbe E, Jobski K, Schmid U. Utilisation of transdermal fentanyl in Germany from 2004 to 2006. Pharmacoepidemiol Drug Saf 2012;21:191–198

    Article  PubMed  Google Scholar 

  18. Arzneimittelkommission der deutschen Ärzteschaft. Die unkritische Anwendung von Fentanylpflastern erhöht das Risiko für schwerwiegende Nebenwirkungen (UAWNews International) Deutsches Ärzteblatt 2012;14:A 724–725

  19. Shomaker TS, Zhang J, Ashburn MA. Assessing the impact of heat on the systemic delivery of fentanyl through the transdermal fentanyl delivery system. Pain Med. 2000 Sep;1(3):225–230

    Article  PubMed  CAS  Google Scholar 

  20. Fröhlich M, Gianotti A, Modell JH. Opioid overdose in a patient using a fentanyl patch during treatment with a warming blanket. Anesth Analg 2001;93:647–648

    Article  Google Scholar 

  21. Sindali K, Sherry K, Sen S, Dheansa B. Life-threatening coma and full-thickness sunburn in a patient treated with transdermal fentanyl patches:a case report. J Med Case Rep. 2012 Jul 26;6(1):220. doi:10.1186/1752-1947-6-220.

    Article  PubMed  Google Scholar 

  22. Matsuki Y, Mizogam M, Tabata M, Matsuki Y, Yasuda Y, Shigemi K. Suspected respiratory depression associated with use of transdermal fentanyl patch. Pain Physician. 2012 Jul-Aug;15(4):E 536–537

    Google Scholar 

  23. Meldung der Arzneimittelkommission der Deutschen Apotheker;Deutsches Ärzteblatt 23. Juli 2010.

  24. Meldung der Bundesvereinigung Deutscher Apothekerverbände, 01. August 2013.

  25. Fachinformationen Fentanyl

  26. Caraceni A, Pigni A, Brunelli C. Is oral morphine still the first choice opioid for moderate to severe cancer pain? A systematic review within the European Palliative Care Research Collaborative guidelines project. Palliat Med 2011;25(5):402–409

    Article  PubMed  Google Scholar 

  27. Gianni W, Ceci M, Bustacchini S, Corsonello A, Abbatecola AM, Brancati AM, Assisi A, Scuteri A, Cipriani L, Lattanzio F. Opioids for the treatment of chronic non-cancer pain in older people. Drugs Aging 2009;26 Suppl 1:63–73

    Article  PubMed  CAS  Google Scholar 

  28. Hunold KM, Esserman DA, Isaacs CG, Dickey RM, Pereira GF, Fillingim RB, Sloane PD, Mc-Lean SA, Platts-Mills TF. Side effects from oral opioids in older adults during the first week of treatment for acute musculoskeletal pain. Acad Emerg Med 2013 Aug 27. doi:10.1111/acem.12212.

    Google Scholar 

  29. King S, Forbes K, Hanks GW, Ferro CJ, Chambers EJ. A systematic review of the use of opioid medication for those with moderate to severe cancer pain and renal impairment:a European Palliative Care Research Collaborative opioid guidelines project. Palliat Med 2011;25(5):525–552

    Article  PubMed  CAS  Google Scholar 

  30. Overholser BR, Foster DR. Opioid pharmacokinetic drug-drug interactions. Am J Manag Care 2011;17 Suppl 11:S276–287

    PubMed  Google Scholar 

  31. Schwender T. Schmerztherapie bei schwer nierenkranken Patienten. Sonderreport Palliativmedizin 2009. Online verfügbar unter:http://www.rosenfluh.ch/rosenfluh/articles/download/690/Schmerztherapie_bei_schwer_nierenkranken_Patienten.pdf;zuletzt aufgerufen am 16.09.2013.

    Google Scholar 

  32. Gustorff B. Opioide in der Therapie alter und dementer Patienten. JATROS Neurologie & Psychiatrie 2008.31. Chan BK, Tam LK, Wat CY, Chung YF, Tsui SL, Cheung CW. Opioids in chronic non-cancer pain. Expert Opin Pharmacother 2011;12(5):705–720

    Google Scholar 

  33. Wolff RF, Aune D, Truyers C, Hernandez AV, Misso K, Riemsma R, Kleijnen J. Systematic review of efficacy and safety of buprenorphine versus fentanyl or morphine in patients with chronic moderate to severe pain. Curr Med Res Opin 2012;28(5):833–845

    Article  PubMed  CAS  Google Scholar 

  34. Combined oral prolonged-release oxycodone and naloxone in opioid-induced bowel dysfunction:review of efficacy and safety data in the treatment of patients experiencing chronic pain. Clemens KE, Mikus G. Expert Opin Pharmacother 2010;11(2):297–310

    Article  PubMed  CAS  Google Scholar 

  35. Mercadante S, Giarratano A. Combined oral prolonged-release oxycodone and naloxone in chronic pain management. Expert Opin Investig Drugs 2013;22(1):161–166

    Article  PubMed  CAS  Google Scholar 

  36. Plosker GL. Buprenorphine 5, 10 and 20 µg/h transdermal patch:a review of its use in the management of chronic non-malignant pain. Drugs 2011;71(18):2491–2509

    Article  PubMed  CAS  Google Scholar 

  37. Überall MA, Müller-Schwefe GH. Low-dose 7-day transdermal buprenorphine in daily clinical practice - perceptions of elderly patients with moderate non-malignant chronic pain. Curr Med Res Opin 2012;28(10):1585–1595

    Article  PubMed  Google Scholar 

  38. Wahle K, Krings D, Schwenke K. Pain therapy in the elderly:7-day transdermal buprenorphine patch in clinical practice. Results of a non-interventional study. MMW Fortschr Med 2013;155 Suppl 1:25–31

    Article  PubMed  Google Scholar 

  39. Almakadma YS, Simpson K. Opioid therapy in non-cancer chronic pain patients:Trends and efficacy in different types of pain, patients age and gender. Saudi J Anaesth 2013;7(3):291–295

    Article  PubMed  Google Scholar 

  40. Chan BK, Tam LK, Wat CY, Chung YF, Tsui SL, Cheung CW. Opioids in chronic non-cancer pain. Expert Opin Pharmacother 2011;12(5):705–720

    Article  PubMed  Google Scholar 

  41. Noble M, Treadwell JR, Tregear SJ, Coates VH, Wiffen PJ, Akafomo C, Schoelles KM. Longterm opioid management for chronic noncancer pain. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.:CD006605. DOI:10.1002/14651858. CD006605.pub2.

    Google Scholar 

  42. Tzschentke TM, Jahnel U, Kogel B et al. Tapentadol hydrochloride:a next-generation, centrally acting analgesic with two mechanisms of action in a single molecule. Drugs Today 2009;45(7):483–496

    PubMed  CAS  Google Scholar 

  43. Riemsma R, Forbes C, Harker J, Worthy G, Misso K, Schäfer M, Kleijnen J, Stürzebecher S. Systematic review of tapentadol in chronic severe pain. Curr Med Res Opin. 2011 Oct;27(10):1907–1930

    Article  PubMed  CAS  Google Scholar 

  44. Merchant S, Provenzano D, Mody S, Ho KF, Etropolski M. Composite measure to assess efficacy/gastrointestinal tolerability of tapentadol ER versus oxycodone CR for chronic pain:pooled analysis of randomized studies. J Opioid Manag 2013;9(1):51–61

    Article  PubMed  Google Scholar 

  45. Meske DS, Xie JY, Oyarzo J, Badghisi H, Ossipov MH, Porreca F. Opioid and noradrenergic contributions of tapentadol in experimental neuropathic pain. Neurosci Lett. 2013 Aug 19. doi:pii:S0304-3940(13)00750-7. 10.1016/j. neulet.2013.08.017.

    Google Scholar 

  46. Christoph T, Schroder W, Tallarida RJ, Devry J, Tzschentke TM. Spinal-supraspinal and intrinsic µ-opioid receptor agonist-norepinephrine reuptake inhibitor (MOR-NRI) synergy of tapentadol in diabetic heat hyperalgesia in mice. J Pharmacol Exp Ther 2013 Sep 19 [Epub ahead of print]

    Google Scholar 

  47. Manchikanti L, Ailinani H, Koyyalagunta D, Datta S, Singh V, Eriator I, Sehgal N, Shah R, Benyamin R, Vallejo R, Fellows B, Christo PJ. A systematic review of randomized trials of long-term opioid management for chronic non-cancer pain. Pain Physician 2011;14(2):91–121

    PubMed  Google Scholar 

  48. van Ojik AL, Jansen PA, Brouwers JR, van Roon EN. Treatment of chronic pain in older people:evidence-based choice of strong-acting opioids. Drugs Aging 2012;29(8):615–625

    Article  PubMed  Google Scholar 

  49. Zeppetella G. The WHO analgesic ladder:25 years on. Br J Nurs 2011;20(17):S4–6

    PubMed  Google Scholar 

  50. Simon ST, Köskeroglu P, Gaertner J, Voltz R. Fentanyl for the Relief of Refractory Breathlessness: A systematic review. J Pain Symptom Manage 2013 Jun 4. pii:S0885-3924(13)00239-X

    Google Scholar 

  51. Maier C, Kindler D. Medikamentöse Schmerztherapie–Analgetika. In Diener H. Ch. und Maier C. (Hrsg). Schmerztherapie (2. Aufl.). Urban & Fischer

  52. Strand MC, Fjeld B, Arnestad M, Mørland J. Can patients receiving opioid maintenance therapy safely drive? A systematic review of epidemiological and experimental studies on driving ability with a focus on concomitant methadone or buprenorphine administration. Traffic Inj Prev 2013;14(1):26–38

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institut für Neurowissenschaften, Algesiologie & Pädiatrie, Nürnberg, Deutschland

    Michael A. Überall

Authors
  1. Michael A. Überall
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael A. Überall.

Additional information

This article is part of a supplement not sponsored by the industry.

Interessenskonflikt

Der Autor erklärt, dass er sich bei der Erstellung des Beitrages von keinen wirtschaftlichen Interessen leiten ließen. Er legt folgende potenzielle Interessenkonflikte offen: Honorare für Vorträge oder Beratungsaktivität von Almirall-Hermal, Archimedes, Bene-Arzneimittel, Grünenthal, Janssen-Cilag, MSD, Mucos, Mundipharma, Pfizer, ProStrakan, TEVA.

Der Verlag erklärt, dass die inhaltliche Qualität des Beitrags von zwei unabhängigen Gutachtern geprüft wurde. Werbung in dieser Zeitschriftenausgabe hat keinen Bezug zur CME-Fortbildung. Der Verlag garantiert, dass die CME-Fortbildung sowie die CME-Fragen frei sind von werblichen Aussagen und keinerlei Produktempfehlungen enthalten. Dies gilt insbesondere für Präparate, die zur Therapie des dargestellten Krankheitsbildes geeignet sind.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Überall, M.A. Chancen optimieren, Risiken minimieren. MMW - Fortschritte der Medizin 155, 63–71 (2013). https://doi.org/10.1007/s15006-013-2127-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15006-013-2127-y

Keywords - Use of strong opioids in general practice

Search

Navigation